NCT04361331View on ClinicalTrials.gov

Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

March 6, 2020

Primary Completion Date

September 1, 2023

Study Completion Date

September 1, 2023

Conditions
Cholangiocarcinoma, Intrahepatic
Interventions
DRUG

Lenvatinib combined with gemox

Arm2: Lenvatinib + gemox

DRUG

Toripalimab combined with lenvatinib

Toripalimab combined with lenvatinib

Trial Locations (2)

200032

Zhongshan hospital, Shanghai

Huang xiaoyong, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER

NCT04361331 - Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma | Biotech Hunter | Biotech Hunter